Canget BioTekpharma, founded by Dr. Fengzhi Li, is a biotech and biopharma company spun off from Roswell Park Cancer Institute. Specializing in the development of novel, cancer-targeting anticancer agents, Canget aims to overcome the major challenges in cancer management, including drug toxicity with limited antitumor efficacy, cancer resistance to treatment, and cancer metastasis.

By focusing on providing highly effective, low toxic, and cancer-targeting anticancer agents, Canget aims to dramatically improve cancer patient survival times and rates, eliminating cancer cell drug resistance and tumor metastasis/relapse. Canget collaborates with Roswell Park Cancer Institute, the first cancer institution in the US, and a National Cancer Institute-designated Comprehensive Cancer Center. With the vision to establish a best practice in innovation and drug development, Canget strives to improve the quality of life and lifespan of cancer patients while making valuable contributions to local communities, national economies, and society through charitable activities.

Canget BioTekpharma is committed to revolutionizing cancer treatment and making a positive impact in the fight against cancer